Keytruda + Avastin + chemo for ovarian cancer with minimal remaining disease
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a combination of three drugs—pembrolizumab (Keytruda, an immunotherapy), bevacizumab (Avastin, a blood-vessel blocker), and oral cyclophosphamide (a chemotherapy pill)—for women with high-grade ovarian cancer who have only tiny bits of disease left after finishing their initial treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have high-grade ovarian cancer (not mucinous or low-grade).
- You must have finished at least 6 cycles of standard platinum and taxane chemotherapy (with or without Avastin) and have minimal residual disease—either found during a second-look surgery or through a special blood test called Signatera.
- You must not have been treated with immunotherapy (like Keytruda) before, and you must not have a known BRCA mutation or HRD positive tumor.
- You need to have good organ function (kidneys, liver, blood counts) and be generally healthy (able to do daily activities with little help).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination treatment for ovarian cancer that has come back after earlier treatment. It aims to see if the combination can shrink tumors or slow the disease, and it may be an option for people whose cancer has become resistant to platinum-based chemotherapy.
This trial tests a new drug combination (trastuzumab rezetecan plus carboplatin) with or without bevacizumab, compared to standard chemotherapy, for ovarian cancer that has come back after platinum-based treatment. It aims to see if this combination works better than the usual options.
This trial is testing a combination of two new immunotherapy drugs (iparomlimab and tuvonralimab) given before surgery and together with chemotherapy for advanced ovarian cancer. It aims to see if this approach can shrink the cancer more effectively and improve outcomes.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This study tests whether adding a targeted therapy (trastuzumab) to the usual maintenance drug (bevacizumab) helps keep ovarian cancer from coming back after first-line chemo. It is for people with certain genetic markers and who have completed initial treatment without the cancer growing.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.